

## **Neuromodulation Market by Type (Internal (Deep Brain Stimulation, Vagus Nerve Stimulation), External (Transcranial Magnetic Stimulation)), Application (Parkinson's Disease, Depression, Urine incontinence, Epilepsy, Obesity) - Global Forecast to 2027**

Market Report | 2022-08-04 | 207 pages | MarketsandMarkets

### **AVAILABLE LICENSES:**

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

### **Report description:**

The global neuromodulation market is valued at an estimated USD 6.0 billion in 2022 and is projected to reach USD 10.4 billion by 2027, at a CAGR of 11.8% during the forecast period. Market growth is driven by factors such as the growing incidence of rising incidence of Parkinson's disease, high incidence of urine incontinence, extensive use of external neuromodulation in healthcare, low cost and ease of use are the major factors hampering the growth of this market.

"The internal neuromodulation segment accounted for the highest growth rate in the neuromodulation market, by product, during the forecast period"

The neuromodulation market is segmented into Internal neuromodulation and external neuromodulation. The internal neuromodulation is expected to register the highest growth rate during the forecast period. Factors such as the minimally invasive nature, reduced physical impact and improved quality of life are contributing to the growth of this segment.

"Deep Brain Stimulation segment accounted for the highest CAGR"

Based on type, the internal neuromodulation market is segmented into spinal cord stimulation (SCS), deep brain stimulation (DBS), vagus nerve stimulation (VNS), sacral nerve stimulation (SNS), and gastric electrical stimulation (GES). Deep brain stimulation segment is expected to register highest growth rate during forecast period as DBS is a minimally invasive technique that allows the stimulation parameters to be changed to reduce side effects.

"The Asia Pacific market is expected to grow at the highest CAGR during the forecast period"

The global neuromodulation market is segmented into five regions - North America, Europe, the Asia Pacific, and Rest of the World. The Asia Pacific region is expected to witness the highest growth in the neuromodulation market during the forecast period. The high growth in this region can primarily be attributed to the increasing geriatric population, and high disease burden of neurological disorders among senior population

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

The primary interviews conducted for this report can be categorized as follows:

- By Company Type: Tier 1 - 28%, Tier 2 - 42%, and Tier 3 - 30%
- By Designation: C-level - 30%, D-level - 34%, and Others - 36%
- By Region: North America - 46%, Europe - 25%, Asia Pacific - 18%, and the Rest of the World - 11%

Lists of Companies Profiled in the Report:

- Medtronic (Ireland)
- Boston Scientific Corporation (US)
- Abbott Laboratories (US)
- LivaNova (UK)
- NeuroPace (US)
- Neuronetics (US)
- Helius Medical Technologies (US)
- Renishaw (UK)
- GTX Medical (Netherlands)
- Bioinduction (UK)
- Bioness (US)
- Nevro Corporation (US)
- BlueWind Medical (Israel)
- Aleva Neurotherapeutics (Switzerland)
- GiMer Medical (Taiwan)
- NeuroSigma (US)
- BioWaveGo USA (US)
- Synapse Biomedical (US)
- Cardionomic (US)
- Theranica Bio-Electronics (Israel)
- MicroTransponder (US)
- Soterix Medical (US)
- Saluda Medical (US)
- Electrocore, Inc. (US)
- tVNS Technologies (Germany).

Research Coverage:

This report provides a detailed picture of the global neuromodulation market. It aims at estimating the size and future growth potential of the market across different segments, such as type, application and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall neuromodulation market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities and challenges.

**Table of Contents:**

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

1	INTRODUCTION	32
1.1	STUDY OBJECTIVES	32
1.2	MARKET DEFINITION	32
1.2.1	INCLUSIONS AND EXCLUSIONS	33
1.3	MARKET SCOPE	33
1.3.1	NEUROMODULATION MARKET SEGMENTATION	33
1.3.2	YEARS CONSIDERED	34
1.4	CURRENCY CONSIDERED	34
1.5	STAKEHOLDERS	34
1.6	SUMMARY OF CHANGES	35
2	RESEARCH METHODOLOGY	36
2.1	RESEARCH DATA	36
	FIGURE 1 RESEARCH DESIGN	36
2.1.1	SECONDARY DATA	37
2.1.1.1	Secondary sources	38
2.1.2	PRIMARY DATA	38
2.1.2.1	Key data from primary sources	39
2.1.2.2	Key industry insights	40
	TABLE 1 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS	40
	FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION	41
2.2	MARKET SIZE ESTIMATION	41
2.2.1	BOTTOM-UP APPROACH	42
	FIGURE 3 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH	42
	FIGURE 4 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH	43
	FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS	43
2.3	MARKET BREAKDOWN AND DATA TRIANGULATION	44
	FIGURE 6 DATA TRIANGULATION METHODOLOGY	44
2.4	MARKET SHARE ANALYSIS	45
2.5	ASSUMPTIONS	45
2.6	RISK ASSESSMENT	45
	TABLE 2 RISK ASSESSMENT: NEUROMODULATION MARKET	45
2.7	LIMITATIONS	46
2.7.1	METHODOLOGY-RELATED LIMITATIONS	46
2.7.2	SCOPE-RELATED LIMITATIONS	46
	?	
3	EXECUTIVE SUMMARY	47
	FIGURE 7 NEUROMODULATION MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION)	47
	FIGURE 8 INTERNAL NEUROMODULATION MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION)	48
	FIGURE 9 EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION)	48
	FIGURE 10 NEUROMODULATION MARKET: GEOGRAPHIC SNAPSHOT	49
4	PREMIUM INSIGHTS	50
4.1	NEUROMODULATION MARKET OVERVIEW	50
	FIGURE 11 RISING PREVALENCE OF NEUROLOGICAL DISORDERS TO DRIVE GROWTH IN NEUROMODULATION MARKET	50
4.2	NORTH AMERICA: NEUROMODULATION MARKET, BY TYPE & COUNTRY (2021)	50
	FIGURE 12 INTERNAL NEUROMODULATION ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2021	50
4.3	GEOGRAPHIC GROWTH OPPORTUNITIES IN NEUROMODULATION MARKET	51
	FIGURE 13 COUNTRIES IN ASIA PACIFIC TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD	51

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5	MARKET OVERVIEW	52
5.1	INTRODUCTION	52
5.2	MARKET DYNAMICS	52
FIGURE 14	NEUROMODULATION MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES	52
5.2.1	DRIVERS	53
5.2.1.1	Rising prevalence of neurological disorders and nerve injuries	53
5.2.1.2	Growing focus on neuromodulation & neurostimulation technologies	53
5.2.1.3	Expanding applications of neuromodulation	54
TABLE 3	INDICATIVE LIST OF NEUROMODULATION CLINICAL TRIALS	54
FIGURE 15	RESEARCH PAPERS PUBLISHED (2011-2021)	55
5.2.1.4	Growing geriatric population and subsequent increase in prevalence of neurological disorders	55
5.2.1.5	Government support for research on neurological disorders	56
FIGURE 16	FUNDING FOR RESEARCH BY NIH (US)	56
5.2.2	RESTRAINTS	57
5.2.2.1	High cost of neuromodulation procedures	57
5.2.3	OPPORTUNITIES	57
5.2.3.1	Emerging economies	57
FIGURE 17	GROWTH IN CURRENT PER CAPITA HEALTHCARE EXPENDITURE, 2012-2019	57
5.2.4	CHALLENGES	58
5.2.4.1	Stringent regulatory frameworks and time-consuming approval processes	58
5.2.4.2	Preference for drug therapies over neuromodulation products	58
5.2.4.3	Shortage of trained professionals	58
5.2.4.4	Product recalls	58
TABLE 4	MAJOR PRODUCT RECALLS	59
5.3	SCENARIO-BASED MARKET ASSESSMENT	60
5.3.1	NEUROMODULATION MARKET	60
FIGURE 18	PESSIMISTIC SCENARIO	60
FIGURE 19	OPTIMISTIC SCENARIO	60
FIGURE 20	REALISTIC SCENARIO	61
5.4	VALUE CHAIN ANALYSIS	61
FIGURE 21	VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASE	62
5.4.1	RESEARCH & DEVELOPMENT	62
5.4.2	MANUFACTURING & ASSEMBLY	62
5.4.3	DISTRIBUTION, MARKETING & SALES, AND POST-SALES SERVICES	62
5.5	SUPPLY CHAIN ANALYSIS	63
FIGURE 22	DIRECT DISTRIBUTION-PREFERRED STRATEGY FOR PROMINENT COMPANIES	63
5.6	TECHNOLOGY ANALYSIS	64
5.7	PORTER'S FIVE FORCES ANALYSIS	64
5.7.1	THREAT FROM NEW ENTRANTS	65
5.7.2	INTENSITY OF COMPETITIVE RIVALRY	65
5.7.3	BARGAINING POWER OF BUYERS	65
5.7.4	BARGAINING POWER OF SUPPLIERS	65
5.7.5	THREAT FROM SUBSTITUTES	65
5.8	KEY STAKEHOLDERS AND BUYING CRITERIA	66
5.8.1	KEY STAKEHOLDERS IN THE BUYING PROCESS	66
FIGURE 23	INFLUENCE OF STAKEHOLDERS ON THE BUYING PROCESS, BY TECHNOLOGY	66
TABLE 5	INFLUENCE OF STAKEHOLDERS ON THE BUYING PROCESS FOR THE TOP 3 TECHNOLOGIES (%)	66

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

## 5.8.2 BUYING CRITERIA 66

FIGURE 24 KEY BUYING CRITERIA FOR TOP 2 END USERS 66

TABLE 6 KEY BUYING CRITERIA, BY END USER 67

## 5.9 REGULATORY LANDSCAPE 67

TABLE 7 INDICATIVE LIST OF REGULATORY AUTHORITIES GOVERNING NEUROMODULATION 67

### 5.9.1 BY REGION 68

#### 5.9.1.1 North America 68

#### 5.9.1.2 Europe 68

#### 5.9.1.3 Asia Pacific 69

##### 5.9.1.3.1 India 69

##### 5.9.1.3.2 China 69

### 5.10 PATENT ANALYSIS 69

?

### 5.11 KEY CONFERENCES AND EVENTS IN 2022 70

TABLE 8 LIST OF CONFERENCES & EVENTS 70

### 5.12 PRICING ANALYSIS 71

TABLE 9 PRICE RANGE FOR NEUROMODULATION DEVICES AND PROCEDURES 71

### 5.13 TRADE ANALYSIS 72

TABLE 10 IMPORT DATA FOR HS CODE 901890, BY COUNTRY, 2016-2020 (USD MILLION) 72

TABLE 11 EXPORT DATA FOR HS CODE 901890, BY COUNTRY, 2016-2020 (USD MILLION) 72

### 5.14 ECOSYSTEM ANALYSIS 73

#### 5.14.1 ROLE IN ECOSYSTEM 73

#### 5.14.2 KEY PLAYERS IN THE NEUROMODULATION MARKET 74

### 5.15 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES 74

## 6 NEUROMODULATION MARKET, BY TYPE 75

### 6.1 INTRODUCTION 76

TABLE 12 NEUROMODULATION MARKET, BY TYPE, 2020-2027 (USD MILLION) 76

### 6.2 INTERNAL NEUROMODULATION 76

TABLE 13 INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020-2027 (USD MILLION) 77

TABLE 14 INTERNAL NEUROMODULATION MARKET, BY REGION, 2020-2027 (USD MILLION) 77

TABLE 15 NORTH AMERICA: INTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 77

TABLE 16 EUROPE: INTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 78

TABLE 17 ASIA PACIFIC: INTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 78

TABLE 18 REST OF THE WORLD: INTERNAL NEUROMODULATION MARKET, BY REGION, 2020-2027 (USD MILLION) 78

#### 6.2.1 SPINAL CORD STIMULATION 79

##### 6.2.1.1 Growing incidence of spinal cord injuries to support market growth 79

TABLE 19 SPINAL CORD STIMULATION MARKET, BY REGION, 2020-2027 (USD MILLION) 80

TABLE 20 SPINAL CORD STIMULATION MARKET, BY REGION, 2020-2027 (UNITS) 80

TABLE 21 NORTH AMERICA: SPINAL CORD STIMULATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 80

TABLE 22 EUROPE: SPINAL CORD STIMULATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 81

TABLE 23 ASIA PACIFIC: SPINAL CORD STIMULATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 81

TABLE 24 REST OF THE WORLD: SPINAL CORD STIMULATION MARKET, BY REGION, 2020-2027 (USD MILLION) 81

#### 6.2.2 DEEP BRAIN STIMULATION 82

##### 6.2.2.1 DBS allows stimulation parameters to be changed to reduce side effects 82

TABLE 25 DEEP BRAIN STIMULATION MARKET, BY REGION, 2020-2027 (USD MILLION) 82

TABLE 26 DEEP BRAIN STIMULATION MARKET, BY REGION, 2020-2027 (UNITS) 83

TABLE 27 NORTH AMERICA: DEEP BRAIN STIMULATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 83

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 28 □ EUROPE: DEEP BRAIN STIMULATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION) □83

TABLE 29 □ ASIA PACIFIC: DEEP BRAIN STIMULATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION) □84

TABLE 30 □ REST OF THE WORLD: DEEP BRAIN STIMULATION MARKET, BY REGION, 2020-2027 (USD MILLION) □84

6.2.3 □ VAGUS NERVE STIMULATION □84

6.2.3.1 □ Non-invasive vagus nerve stimulation does not require surgical implantation-a key benefit □84

TABLE 31 □ VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2027 (USD MILLION) □85

TABLE 32 □ VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2027 (UNITS) □85

TABLE 33 □ NORTH AMERICA: VAGUS NERVE STIMULATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION) □85

TABLE 34 □ EUROPE: VAGUS NERVE STIMULATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION) □86

TABLE 35 □ ASIA PACIFIC: VAGUS NERVE STIMULATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION) □86

TABLE 36 □ REST OF THE WORLD: VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2027 (USD MILLION) □86

6.2.4 □ SACRAL NERVE STIMULATION □87

6.2.4.1 □ Widening scope of sacral nerve stimulation to drive growth □87

TABLE 37 □ SACRAL NERVE STIMULATION DEVICES OFFERED □87

TABLE 38 □ SACRAL NERVE STIMULATION MARKET, BY REGION, 2020-2027 (USD MILLION) □87

TABLE 39 □ SACRAL NERVE STIMULATION MARKET, BY REGION, 2020-2027 (UNITS) □88

TABLE 40 □ NORTH AMERICA: SACRAL NERVE STIMULATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION) □88

TABLE 41 □ EUROPE: SACRAL NERVE STIMULATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION) □88

TABLE 42 □ ASIA PACIFIC: SACRAL NERVE STIMULATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION) □89

TABLE 43 □ REST OF THE WORLD: SACRAL NERVE STIMULATION MARKET, BY REGION, 2020-2027 (USD MILLION) □89

6.2.5 □ GASTRIC ELECTRICAL STIMULATION □89

6.2.5.1 □ Growing number of people suffering from severe GERD and gastroparesis to fuel market growth □89

TABLE 44 □ GASTRIC ELECTRICAL STIMULATION MARKET, BY REGION, 2020-2027 (USD MILLION) □90

TABLE 45 □ GASTRIC ELECTRICAL STIMULATION MARKET, BY REGION, 2020-2027 (UNITS) □90

TABLE 46 □ NORTH AMERICA: GASTRIC ELECTRICAL STIMULATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION) □90

TABLE 47 □ EUROPE: GASTRIC ELECTRICAL STIMULATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION) □91

TABLE 48 □ ASIA PACIFIC: GASTRIC ELECTRICAL STIMULATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION) □91

TABLE 49 □ REST OF THE WORLD: GASTRIC ELECTRICAL STIMULATION MARKET, BY REGION, 2020-2027 (USD MILLION) □91

6.3 □ EXTERNAL NEUROMODULATION □92

TABLE 50 □ EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020-2027 (USD MILLION) □92

TABLE 51 □ EXTERNAL NEUROMODULATION MARKET, BY REGION, 2020-2027 (USD MILLION) □92

TABLE 52 □ NORTH AMERICA: EXTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION) □92

TABLE 53 □ EUROPE: EXTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION) □93

TABLE 54 □ ASIA PACIFIC: EXTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION) □93

TABLE 55 □ REST OF THE WORLD: EXTERNAL NEUROMODULATION MARKET, BY REGION, 2020-2027 (USD MILLION) □93

6.3.1 □ TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION □94

6.3.1.1 □ Extensive use in healthcare, low cost, and ease of use to favor market growth □94

TABLE 56 □ TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY REGION, 2020-2027 (USD MILLION) □94

TABLE 57 □ TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY REGION, 2020-2027 (UNITS) □95

TABLE 58 □ NORTH AMERICA: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION) □95

TABLE 59 □ EUROPE: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION) □95

TABLE 60 □ ASIA PACIFIC: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION) □96

TABLE 61 □ REST OF THE WORLD: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY REGION, 2020-2027 (USD MILLION) □96

6.3.2 □ TRANSCRANIAL MAGNETIC STIMULATION □96

6.3.2.1 □ Minimal patient discomfort associated with TMS supports demand □96

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 62	TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY REGION, 2020-2027 (USD MILLION)	97
TABLE 63	TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY REGION, 2020-2027 (UNITS)	97
TABLE 64	NORTH AMERICA: TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION)	97
TABLE 65	EUROPE: TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION)	98
TABLE 66	ASIA PACIFIC: TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION)	98
TABLE 67	REST OF THE WORLD: TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY REGION, 2020-2027 (USD MILLION)	98
?		
6.3.3	RESPIRATORY ELECTRICAL STIMULATION	99
6.3.3.1	High treatment efficacy to fuel market growth	99
TABLE 68	RESPIRATORY ELECTRICAL STIMULATION MARKET, BY REGION, 2020-2027 (USD MILLION)	99
TABLE 69	RESPIRATORY ELECTRICAL STIMULATION MARKET, BY REGION, 2020-2027 (UNITS)	99
TABLE 70	NORTH AMERICA: RESPIRATORY ELECTRICAL STIMULATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION)	100
TABLE 71	EUROPE: RESPIRATORY ELECTRICAL STIMULATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION)	100
TABLE 72	ASIA PACIFIC: RESPIRATORY ELECTRICAL STIMULATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION)	100
TABLE 73	REST OF THE WORLD: RESPIRATORY ELECTRICAL STIMULATION MARKET, BY REGION, 2020-2027 (USD MILLION)	101
7	NEUROMODULATION MARKET, BY APPLICATION	102
7.1	INTRODUCTION	103
7.2	SPINAL CORD STIMULATION MARKET, BY APPLICATION	103
TABLE 74	SPINAL CORD STIMULATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION)	103
7.2.1	CHRONIC PAIN	103
7.2.1.1	High incidence of chronic pain supports market growth	103
TABLE 75	SPINAL CORD STIMULATION MARKET FOR CHRONIC PAIN, BY REGION, 2020-2027 (USD MILLION)	103
7.2.2	FAILED BACK SURGERY SYNDROME	104
7.2.2.1	Growing incidence of FBSS due to rising number of surgeries each year to drive demand for stimulation technologies	104
TABLE 76	SPINAL CORD STIMULATION MARKET FOR FAILED BACK SURGERY SYNDROME, BY REGION, 2020-2027 (USD MILLION)	104
7.2.3	ISCHEMIA	104
7.2.3.1	High effectiveness of neuromodulation for ischemia treatment to support market growth	104
TABLE 77	SPINAL CORD STIMULATION MARKET FOR ISCHEMIA, BY REGION, 2020-2027 (USD MILLION)	105
7.3	DEEP BRAIN STIMULATION MARKET, BY APPLICATION	105
TABLE 78	DEEP BRAIN STIMULATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION)	105
7.3.1	PARKINSON'S DISEASE	105
7.3.1.1	Rising incidence of Parkinson's disease and growing R&D activity in this area to drive growth	105
TABLE 79	DEEP BRAIN STIMULATION MARKET FOR PARKINSON'S DISEASE, BY REGION, 2020-2027 (USD MILLION)	106
7.3.2	TREMORS	106
7.3.2.1	High efficacy of DBS in treating tremors boosts demand	106
TABLE 80	DEEP BRAIN STIMULATION MARKET FOR TREMORS, BY REGION, 2020-2027 (USD MILLION)	106
?		
7.3.3	DEPRESSION	107
7.3.3.1	Lack of evidence of efficacy of DBS for depression treatment to limit market growth	107
TABLE 81	DEEP BRAIN STIMULATION MARKET FOR DEPRESSION, BY REGION, 2020-2027 (USD MILLION)	107
7.3.4	OTHER DBS APPLICATIONS	107
TABLE 82	DEEP BRAIN STIMULATION MARKET FOR OTHER DBS APPLICATIONS, BY REGION, 2020-2027 (USD MILLION)	108
7.4	SACRAL NERVE STIMULATION MARKET, BY APPLICATION	108
TABLE 83	SACRAL NERVE STIMULATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION)	108
7.4.1	URINE INCONTINENCE	108
7.4.1.1	High incidence of urine incontinence offers growth opportunities	108
TABLE 84	SACRAL NERVE STIMULATION MARKET FOR URINE INCONTINENCE, BY REGION, 2020-2027 (USD MILLION)	109

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

#### 7.4.2 □FECAL INCONTINENCE □109

7.4.2.1 □Reduced symptom recurrence supports use of SNS in fecal incontinence treatment □109

TABLE 85 □SACRAL NERVE STIMULATION MARKET FOR FECAL INCONTINENCE, BY REGION, 2020-2027 (USD MILLION) □109

#### 7.5 □VAGUS NERVE STIMULATION MARKET, BY APPLICATION □110

TABLE 86 □VAGUS NERVE MARKET, BY APPLICATION, 2020-2027 (USD MILLION) □110

#### 7.5.1 □EPILEPSY □110

7.5.1.1 □Advantages associated with VNS in epilepsy treatment to propel market □110

TABLE 87 □VAGUS NERVE STIMULATION MARKET FOR EPILEPSY, BY REGION, 2020-2027 (USD MILLION) □110

#### 7.5.2 □OTHER VNS APPLICATIONS □110

TABLE 88 □VAGUS NERVE STIMULATION MARKET FOR OTHER VNS APPLICATIONS, BY REGION, 2020-2027 (USD MILLION) □111

#### 7.6 □GASTRIC ELECTRICAL STIMULATION MARKET, BY APPLICATION □111

TABLE 89 □GASTRIC ELECTRICAL STIMULATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) □111

#### 7.6.1 □GASTROPARESIS □111

7.6.1.1 □GES treatment reduces hospitalizations for patients affected by gastroparesis □111

TABLE 90 □GASTRIC ELECTRICAL STIMULATION MARKET FOR GASTROPARESIS, BY REGION, 2020-2027 (USD MILLION) □112

#### 7.6.2 □OBESITY □112

7.6.2.1 □Risks associated with gastric bypass to increase preference for GES □112

TABLE 91 □GASTRIC ELECTRICAL STIMULATION MARKET FOR OBESITY, BY REGION, 2020-2027 (USD MILLION) □112

#### 7.7 □TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY APPLICATION □113

TABLE 92 □TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) □113

?

#### 7.7.1 □TREATMENT-RESISTANT DEPRESSION □113

7.7.1.1 □TENS induces relaxed state in patients suffering from treatment-resistant depression □113

TABLE 93 □TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET FOR TREATMENT-RESISTANT DEPRESSION, BY REGION, 2020-2027 (USD MILLION) □113

#### 7.7.2 □OTHER TENS APPLICATIONS □113

TABLE 94 □TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET FOR OTHER TENS APPLICATIONS, BY REGION, 2020-2027 (USD MILLION) □114

#### 7.8 □TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY APPLICATION □114

TABLE 95 □TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) □114

#### 7.8.1 □DEPRESSION □114

7.8.1.1 □Increased acceptance among patients to drive demand for TMS □114

TABLE 96 □TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR DEPRESSION, BY REGION, 2020-2027 (USD MILLION) □115

#### 7.8.2 □MIGRAINE □115

7.8.2.1 □High prevalence of migraine to support market growth □115

TABLE 97 □TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR MIGRAINE, BY REGION, 2020-2027 (USD MILLION) □115

#### 7.9 □RESPIRATORY ELECTRICAL STIMULATION MARKET, BY APPLICATION □116

#### 7.9.1 □SPINAL CORD INJURY □116

7.9.1.1 □Rising incidence of spinal cord injuries ensures sustained demand for RES □116

TABLE 98 □RESPIRATORY ELECTRICAL STIMULATION MARKET FOR SPINAL CORD INJURY, BY REGION, 2020-2027 (USD MILLION) □116

#### 8 □NEUROMODULATION MARKET, BY REGION □117

#### 8.1 □INTRODUCTION □118

TABLE 99 □NEUROMODULATION MARKET, BY REGION, 2020-2027 (USD MILLION) □118

#### 8.2 □NORTH AMERICA □118

FIGURE 25 □NORTH AMERICA: NEUROMODULATION MARKET SNAPSHOT □119

TABLE 100 □NORTH AMERICA: NEUROMODULATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION) □120

TABLE 101 □NORTH AMERICA: NEUROMODULATION MARKET, BY TYPE, 2020-2027 (USD MILLION) □120

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 102 NORTH AMERICA: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020-2027 (USD MILLION) 120

TABLE 103 NORTH AMERICA: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020-2027 (USD MILLION) 121

TABLE 104 NORTH AMERICA: SPINAL CORD STIMULATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 121

TABLE 105 NORTH AMERICA: DEEP BRAIN STIMULATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 121

TABLE 106 NORTH AMERICA: SACRAL NERVE STIMULATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 122

TABLE 107 NORTH AMERICA: VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 122

TABLE 108 NORTH AMERICA: GASTRIC ELECTRICAL STIMULATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 122

TABLE 109 NORTH AMERICA: TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 122

TABLE 110 NORTH AMERICA: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 123

8.2.1 US 123

8.2.1.1 Large number of prominent players makes US the largest market 123

TABLE 111 US: NEUROMODULATION MARKET, BY TYPE, 2020-2027 (USD MILLION) 124

TABLE 112 US: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020-2027 (USD MILLION) 124

TABLE 113 US: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020-2027 (USD MILLION) 125

8.2.2 CANADA 125

8.2.2.1 Rising healthcare expenditure and increasing disease prevalence will drive demand for neurostimulation 125

TABLE 114 NEUROLOGICAL CONDITIONS PREVALENT IN CANADA 126

TABLE 115 CANADA: NEUROMODULATION MARKET, BY TYPE, 2020-2027 (USD MILLION) 126

TABLE 116 CANADA: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020-2027 (USD MILLION) 127

TABLE 117 CANADA: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020-2027 (USD MILLION) 127

8.3 EUROPE 127

TABLE 118 EUROPE: NEUROMODULATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 128

TABLE 119 EUROPE: NEUROMODULATION MARKET, BY TYPE, 2020-2027 (USD MILLION) 128

TABLE 120 EUROPE: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020-2027 (USD MILLION) 128

TABLE 121 EUROPE: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020-2027 (USD MILLION) 129

TABLE 122 EUROPE: SPINAL CORD STIMULATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 129

TABLE 123 EUROPE: DEEP BRAIN STIMULATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 129

TABLE 124 EUROPE: SACRAL NERVE STIMULATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 130

TABLE 125 EUROPE: VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 130

TABLE 126 EUROPE: GASTRIC ELECTRICAL STIMULATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 130

TABLE 127 EUROPE: TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 130

TABLE 128 EUROPE: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 131

8.3.1 GERMANY 131

8.3.1.1 Favorable government initiatives ensure strong market growth in Germany 131

TABLE 129 GERMANY: NEUROMODULATION MARKET, BY TYPE, 2020-2027 (USD MILLION) 132

TABLE 130 GERMANY: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020-2027 (USD MILLION) 132

TABLE 131 GERMANY: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020-2027 (USD MILLION) 132

8.3.2 UK 133

8.3.2.1 High public- and private-sector investments fuel market growth 133

TABLE 132 UK: NEUROMODULATION MARKET, BY TYPE, 2020-2027 (USD MILLION) 134

TABLE 133 UK: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020-2027 (USD MILLION) 134

TABLE 134 UK: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020-2027 (USD MILLION) 134

8.3.3 FRANCE 135

8.3.3.1 Availability of insurance and favorable healthcare reforms contribute to growth 135

TABLE 135 FRANCE: NEUROMODULATION MARKET, BY TYPE, 2020-2027 (USD MILLION) 135

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 136 □FRANCE: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020-2027 (USD MILLION) □135

TABLE 137 □FRANCE: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020-2027 (USD MILLION) □136

8.3.4 □ITALY □136

8.3.4.1 □Easy access to healthcare services makes Italy a lucrative market □136

TABLE 138 □ITALY: NEUROMODULATION MARKET, BY TYPE, 2020-2027 (USD MILLION) □136

TABLE 139 □ITALY: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020-2027 (USD MILLION) □137

TABLE 140 □ITALY: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020-2027 (USD MILLION) □137

8.3.5 □SPAIN □137

8.3.5.1 □Growing government initiatives may support market growth in Spain □137

TABLE 141 □SPAIN: NEUROMODULATION MARKET, BY TYPE, 2020-2027 (USD MILLION) □138

TABLE 142 □SPAIN: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020-2027 (USD MILLION) □138

TABLE 143 □SPAIN: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020-2027 (USD MILLION) □138

8.3.6 □REST OF EUROPE □138

TABLE 144 □PERCENTAGE OF POPULATION AGED 65 YEARS OR OVER, 2019 VS. 2050 □139

TABLE 145 □REST OF EUROPE: NEUROMODULATION MARKET, BY TYPE, 2020-2027 (USD MILLION) □139

TABLE 146 □REST OF EUROPE: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020-2027 (USD MILLION) □140

TABLE 147 □REST OF EUROPE: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020-2027 (USD MILLION) □140

8.4 □ASIA PACIFIC □140

FIGURE 26 □ASIA PACIFIC: NEUROMODULATION MARKET SNAPSHOT □141

TABLE 148 □ASIA PACIFIC: NEUROMODULATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION) □141

TABLE 149 □ASIA PACIFIC: NEUROMODULATION MARKET, BY TYPE, 2020-2027 (USD MILLION) □142

TABLE 150 □ASIA PACIFIC: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020-2027 (USD MILLION) □142

TABLE 151 □ASIA PACIFIC: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020-2027 (USD MILLION) □142

TABLE 152 □ASIA PACIFIC: SPINAL CORD STIMULATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) □143

TABLE 153 □ASIA PACIFIC: DEEP BRAIN STIMULATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) □143

TABLE 154 □ASIA PACIFIC: SACRAL NERVE STIMULATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) □143

TABLE 155 □ASIA PACIFIC: VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) □144

TABLE 156 □ASIA PACIFIC: GASTRIC ELECTRICAL STIMULATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) □144

TABLE 157 □ASIA PACIFIC: TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) □144

TABLE 158 □ASIA PACIFIC: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) □144

8.4.1 □JAPAN □145

8.4.1.1 □Japan dominates the APAC market for neuromodulation □145

TABLE 159 □JAPAN: NEUROMODULATION MARKET, BY TYPE, 2020-2027 (USD MILLION) □145

TABLE 160 □JAPAN: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020-2027 (USD MILLION) □146

TABLE 161 □JAPAN: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020-2027 (USD MILLION) □146

8.4.2 □CHINA □146

8.4.2.1 □Growing geriatric population will favor market growth in China □146

TABLE 162 □CHINA: NEUROMODULATION MARKET, BY TYPE, 2020-2027 (USD MILLION) □147

TABLE 163 □CHINA: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020-2027 (USD MILLION) □147

TABLE 164 □CHINA: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020-2027 (USD MILLION) □147

8.4.3 □INDIA □148

8.4.3.1 □Improvements in healthcare infrastructure in the country will support market □148

TABLE 165 □INDIA: NEUROMODULATION MARKET, BY TYPE, 2020-2027 (USD MILLION) □148

TABLE 166 □INDIA: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020-2027 (USD MILLION) □148

TABLE 167 □INDIA: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020-2027 (USD MILLION) □149

?

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

#### 8.4.4 REST OF ASIA PACIFIC 149

TABLE 168 REST OF ASIA PACIFIC: NEUROMODULATION MARKET, BY TYPE, 2020-2027 (USD MILLION) 150

TABLE 169 REST OF ASIA PACIFIC: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020-2027 (USD MILLION) 150

TABLE 170 REST OF ASIA PACIFIC: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020-2027 (USD MILLION) 150

#### 8.5 REST OF THE WORLD 151

TABLE 171 REST OF THE WORLD: NEUROMODULATION MARKET, BY REGION, 2020-2027 (USD MILLION) 151

TABLE 172 REST OF THE WORLD: NEUROMODULATION MARKET, BY TYPE, 2020-2027 (USD MILLION) 151

TABLE 173 REST OF THE WORLD: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020-2027 (USD MILLION) 152

TABLE 174 REST OF THE WORLD: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020-2027 (USD MILLION) 152

TABLE 175 REST OF THE WORLD: SPINAL CORD STIMULATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 153

TABLE 176 REST OF THE WORLD: DEEP BRAIN STIMULATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 153

TABLE 177 REST OF THE WORLD: SACRAL NERVE STIMULATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 153

TABLE 178 REST OF THE WORLD: VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 153

TABLE 179 REST OF THE WORLD: GASTRIC ELECTRICAL STIMULATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 154

TABLE 180 REST OF THE WORLD: TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY APPLICATION, 2020-2027 (USD

MILLION) 154

TABLE 181 REST OF THE WORLD: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY APPLICATION, 2020-2027 (USD

MILLION) 154

#### 8.5.1 LATIN AMERICA 154

8.5.1.1 Latin America holds largest share of neuromodulation market in RoW 154

TABLE 182 LATIN AMERICA: NEUROMODULATION MARKET, BY TYPE, 2020-2027 (USD MILLION) 155

TABLE 183 LATIN AMERICA: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020-2027 (USD MILLION) 155

TABLE 184 LATIN AMERICA: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020-2027 (USD MILLION) 155

#### 8.5.2 MIDDLE EAST & AFRICA 156

8.5.2.1 High cost of neuromodulation to hamper market growth 156

TABLE 185 MIDDLE EAST & AFRICA: NEUROMODULATION MARKET, BY TYPE, 2020-2027 (USD MILLION) 156

TABLE 186 MIDDLE EAST & AFRICA: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020-2027 (USD MILLION) 156

TABLE 187 MIDDLE EAST & AFRICA: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020-2027 (USD MILLION) 157

?

### 9 COMPETITIVE LANDSCAPE 158

#### 9.1 OVERVIEW 158

##### 9.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 158

TABLE 188 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS 158

##### 9.3 REVENUE SHARE ANALYSIS 159

FIGURE 27 REVENUE ANALYSIS OF KEY PLAYERS IN NEUROMODULATION MARKET 159

##### 9.4 MARKET SHARE ANALYSIS 160

TABLE 189 NEUROMODULATION MARKET: DEGREE OF COMPETITION 160

#### 9.5 COMPANY EVALUATION MATRIX 161

##### 9.5.1 STARS 161

##### 9.5.2 EMERGING LEADERS 161

##### 9.5.3 PERVASIVE PLAYERS 161

##### 9.5.4 PARTICIPANTS 161

FIGURE 28 COMPANY EVALUATION MATRIX: NEUROMODULATION MARKET 162

#### 9.6 COMPANY EVALUATION MATRIX FOR SMES/START-UPS 162

##### 9.6.1 PROGRESSIVE COMPANIES 162

##### 9.6.2 STARTING BLOCKS 162

##### 9.6.3 RESPONSIVE COMPANIES 163

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

9.6.4	DYNAMIC COMPANIES	163
FIGURE 29	COMPANY EVALUATION MATRIX FOR SMES/START-UPS: NEUROMODULATION MARKET	163
9.7	COMPANY FOOTPRINT ANALYSIS	164
TABLE 190	OVERALL FOOTPRINT OF COMPANIES	164
TABLE 191	REGIONAL FOOTPRINT OF COMPANIES	165
TABLE 192	TYPE FOOTPRINT OF COMPANIES	166
9.8	COMPETITIVE BENCHMARKING	167
TABLE 193	NEUROMODULATION MARKET: DETAILED LIST OF KEY START-UPS/SMES	167
9.9	COMPETITIVE SCENARIO	167
9.9.1	PRODUCT LAUNCHES & APPROVALS	167
TABLE 194	KEY PRODUCT LAUNCHES & APPROVALS	167
9.9.2	DEALS	168
TABLE 195	KEY DEALS	168
9.9.3	OTHER DEVELOPMENTS	169
TABLE 196	OTHER KEY DEVELOPMENTS	169
?		
10	COMPANY PROFILES	170
	(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*	
10.1	KEY PLAYERS	170
10.1.1	MEDTRONIC PLC	170
TABLE 197	MEDTRONIC PLC: BUSINESS OVERVIEW	170
FIGURE 30	MEDTRONIC PLC: COMPANY SNAPSHOT (2021)	171
10.1.2	BOSTON SCIENTIFIC CORPORATION	175
TABLE 198	BOSTON SCIENTIFIC CORPORATION: BUSINESS OVERVIEW	175
FIGURE 31	BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT (2021)	176
10.1.3	ABBOTT LABORATORIES	179
TABLE 199	ABBOTT LABORATORIES: BUSINESS OVERVIEW	179
FIGURE 32	ABBOTT LABORATORIES: COMPANY SNAPSHOT (2021)	180
10.1.4	LIVANOVA PLC	182
TABLE 200	LIVANOVA PLC: BUSINESS OVERVIEW	182
FIGURE 33	LIVANOVA PLC: COMPANY SNAPSHOT (2021)	183
10.1.5	NEVRO CORPORATION	185
TABLE 201	NEVRO CORPORATION: BUSINESS OVERVIEW	185
FIGURE 34	NEVRO CORPORATION: COMPANY SNAPSHOT (2021)	185
10.1.6	NEUROSIGMA, INC.	187
TABLE 202	NEUROSIGMA, INC.: BUSINESS OVERVIEW	187
10.1.7	NEUROPACE, INC.	189
TABLE 203	NEUROPACE, INC.: BUSINESS OVERVIEW	189
FIGURE 35	NEUROPACE, INC.: COMPANY SNAPSHOT (2021)	189
10.1.8	SOTERIX MEDICAL INC.	192
TABLE 204	SOTERIX MEDICAL INC.: BUSINESS OVERVIEW	192
10.1.9	SYNAPSE BIOMEDICAL INC.	194
TABLE 205	SYNAPSE BIOMEDICAL INC.: BUSINESS OVERVIEW	194
10.1.10	ALEVA NEUROTHERAPEUTICS SA	195
TABLE 206	ALEVA NEUROTHERAPEUTICS SA: BUSINESS OVERVIEW	195
10.1.11	THERANICA BIO-ELECTRONICS LTD.	196

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 207 □ THERANICA BIO-ELECTRONICS LTD.: BUSINESS OVERVIEW □ 196

10.1.12 □ NEURONETICS □ 197

TABLE 208 □ NEURONETICS: BUSINESS OVERVIEW □ 197

FIGURE 36 □ NEURONETICS: COMPANY SNAPSHOT (2021) □ 198

10.1.13 □ BIONESS □ 200

TABLE 209 □ BIONESS: BUSINESS OVERVIEW □ 200

10.1.14 □ BIOINDUCTION □ 201

TABLE 210 □ BIOINDUCTION: BUSINESS OVERVIEW □ 201

?

10.2 □ OTHER PLAYERS □ 202

10.2.1 □ GIMER MEDICAL □ 202

10.2.2 □ GTX MEDICAL □ 202

10.2.3 □ HELIUS MEDICAL TECHNOLOGIES □ 203

10.2.4 □ MICROTRANSPONDER □ 203

10.2.5 □ BLUEWIND MEDICAL □ 204

10.2.6 □ ELECTROCORE, INC. □ 204

10.2.7 □ RENISHAW PLC □ 205

10.2.8 □ TVNS TECHNOLOGIES GMBH □ 205

10.2.9 □ BIOWAVEGO USA □ 206

10.2.10 □ CARDIONOMIC, INC. □ 206

10.2.11 □ SALUDA MEDICAL PTY LTD. □ 206

\*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

11 □ APPENDIX □ 207

11.1 □ DISCUSSION GUIDE □ 207

11.2 □ KNOWLEDGESTORE: MARKET SAND MARKETS' SUBSCRIPTION PORTAL □ 212

11.3 □ AVAILABLE CUSTOMIZATIONS □ 214

11.4 □ RELATED REPORTS □ 214

11.5 □ AUTHOR DETAILS □ 215

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

**Neuromodulation Market by Type (Internal (Deep Brain Stimulation, Vagus Nerve Stimulation), External (Transcranial Magnetic Stimulation)), Application (Parkinson's Disease, Depression, Urine incontinence, Epilepsy, Obesity) - Global Forecast to 2027**

Market Report | 2022-08-04 | 207 pages | MarketsandMarkets

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Date

2026-06-09

Signature

A large, empty rectangular box with a thin black border, intended for a signature.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)